Boehringer Ingelheim Signs Agreement With Hokkaido-Based Evec
This article was originally published in PharmAsia News
Executive Summary
Major pharmaceutical company Boehringer Ingelheim of Germany signed a license agreement with Evec, a Hokkaido University-based biopharmaceutical venture company. According to the agreement, BI obtains worldwide exclusive rights on development and marketing for one of Evec's human therapeutic antibody programs. In return, Evec could receive up to €55 million in upfront and potential milestone payments. Evec will also receive royalties after the product's market launch. Established in 2003 and based in Sapporo, Hokkaido, Evec utilizes Epstein-Barr virus' lymphoproliferative. (Click here for more - Japanese language